retatrutide type 2 diabetes trial results 2024 Summary of the highest percent weight change in completed phase and Retatrutide produces up to 30.3%

Others prefer morning administration to avoid potential sleep disruption

Clinical studies show that patients using retatrutide experience an average 15% reduction in body weight after following a structured dosing schedule

Results sent to your provider

The phase 2 trial showed 22.8% average weight loss at 48 weeks with the 8mg dose, only 1.4 percentage points less than the 12mg dose

Proc Natl Acad Sci U S A (1990) 87(18):72604.10.1073/pnas.87.18.7260 Summary Keywords glucagon-like peptide-1, osteogenesis, bone resorption, osteoporosis, diabetes mellitus Citation Zhao C, Liang J, Yang Y, Yu M and Qu X (2017) The Impact of Glucagon-Like Peptide-1 on Bone Metabolism and Its Possible Mechanisms

That matters because obesity in midlife is linked with higher dementia risk, likely through these same inflammatory and vascular pathways